At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Sep 21, 2017·Updated Dec 22, 2025
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Lenvatinib for Neuroendocrine Tumors and 2 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to: * Assess overall radiographic response rate (ORR) * Assess progression-free survival (PFS) * Test the safety and tolerability of Pembrolizumab in combination with lenvatinib
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartDec 2017
Primary CompletionJan 2023
Study CompletionMay 2024
TodayJul 2026
First PostedSep 21, 2017
Enrollment StartDec 15, 2017
Primary CompletionJan 10, 2023
Study CompletionMay 13, 2024
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 8.8 years ago
Interventions
Pembrolizumabdrug
200 mg Pembrolizumab by IV on Day 1 of each 3 week cycle.
Lenvatinibdrug
20 mg Lenvatinib by mouth every day of each 3 week cycle